Related Experiment Video
Updated: Oct 11, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.4K
Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
1Department of Pharmacy Practice, Marshall B. Ketchum University College of Pharmacy, Fullerton, CA.
Summary
New ultra-rapid-acting insulins offer faster absorption and improved post-meal glucose control for diabetes management. These advanced insulin options provide similar safety and A1C benefits to existing treatments.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Mellitus Research
Background:
- Bolus insulins are critical for mealtime glucose control and hyperglycemia correction in diabetes management.
- Traditional rapid-acting insulin analogs have been the standard for bolus insulin therapy.
Purpose of the Study:
- To review emerging ultra-rapid-acting insulin analogs.
- To compare their benefits and limitations against existing bolus insulin options.
Main Methods:
- Review of clinical studies on new insulin aspart and insulin lispro-aabc.
- Comparative analysis of efficacy (A1C, postprandial glucose) and safety (hypoglycemia).
Main Results:
- Ultra-rapid-acting insulins demonstrate faster absorption and onset of action due to enhanced formulations.
- Efficacy for A1C reduction and safety profiles are comparable to other rapid-acting insulin analogs.
- Significant reductions in 1- and 2-hour postprandial glucose levels were observed.
Conclusions:
- Ultra-rapid-acting insulins expand therapeutic options, offering enhanced dosing flexibility.
- Shared decision-making is crucial for patient-centered selection of these new insulin formulations.
- These insulins may benefit individuals struggling to meet postprandial glycemic targets.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
303
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
303
01:06Oral Hypoglycemic Agents: Glinides
300
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
300
01:16Insulin: Dosing Regimen and Adverse Effects
300
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
300
01:24Glucagon-like Receptor Agonists
473
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
473
01:25Insulin: Biosynthesis, Chemistry, and Preparation
656
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
656
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.5K